Altimmune Inc(ALT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.79 | Insider Own | 5.59% | Shs Outstand | 194.5M | Perf Week | -11.3% |
| Market Cap | 0.40B | Forward P/E | - | EPS next Y | -9.21% | Insider Trans | 0.14% | Shs Float | 183.6M | Perf Month | -31.08% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | -0.13 | Inst Own | 72.44% | Short Float | 23% | Perf Quarter | -30.14% |
| Income | -0.09B | P/S | 13227.16 | EPS this Y | 41.8% | Inst Trans | 34.48% | Short Ratio | 9.74 | Perf Half Y | -25.55% |
| Sales | 0.00B | P/B | 0.84 | EPS next 5Y | 14.25% | ROA | -25.58% | Short Interest | 42.23M | Perf YTD | -43.49% |
| Book/sh | 2.44 | P/C | 1.22 | EPS past 3/5Y | 17.87% 12.17% | ROE | -28.87% | 52W High | -68.32% ($6.44) | Perf Year | -50.72% |
| Cash/sh | 1.68 | P/FCF | - | Sales past 3/5Y | - -65.33% | ROIC | -17.99% | 52W Low | 0.99% ($2.02) | Perf 3Y | -11.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 33.01% | Gross Margin | -219.35% | Volatility(W/M) | 6.38% 4.73% | Perf 5Y | -81.45% |
| Dividend TTM | - | EV/Sales | 3550.49 | Sales Y/Y TTM | 55% | Oper. Margin | -320725.81% | ATR (14) | 0.12 | Perf 10Y | -97.93% |
| Dividend Ex-Date | - | Quick Ratio | 26.77 | EPS Q/Q | 54.71% | Profit Margin | -296000% | RSI (14) | 21.26 | Recom | 1.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 26.77 | Sales Q/Q | -100% | SMA20 | -15.99% ($2.43) | Beta | 0.12 | Target Price | $17.11 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/8/12 | SMA50 | -29.21% ($2.88) | Rel Volume | 1.15 | Prev Close | $2.05 |
| Employees | 57 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | 13.36% - | SMA200 | -38.41% ($3.31) | Avg Volume(3M) | 4.34M | Price | $2.04 |
| IPO | 2005/10/6 | Option/Short | Yes/Yes | Trades | 11159 | Volume | 4,967,640 | Change | -0.49% |
🧪 Altimmune (ALT) is a US late-stage clinical biopharmaceutical company developing next-generation peptide-based therapeutics for obesity and liver disease. It is researching innovative treatments centered on its lead candidate, pemvidutide, which simultaneously delivers weight loss and liver fat reduction effects.
Over the past 1 year, on the lower side
68% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
ALT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +41.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,322,716. Peers typically go for $1,261.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
BBC Virtus Biotech Clinical Trials ETF <0.01% 
APPC Corgi APP 2x Daily ETF <0.01% 
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
SBIO ALPS Medical Breakthroughs ETF <0.01% 
XBI State Street SPDR S&P Biotech ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
XLV State Street Health Care Select Sector SPDR ETF 46.7B 
VHT Vanguard Health Care ETF 20.0B 
TCAF T. Rowe Price Capital Appreciation Equity ETF 8.0B 
IYH iShares U.S. Healthcare ETF 4.5B 
IXJ iShares Global Healthcare ETF 4.5B It ranks #240 of 594 in the industry
Based on market cap of $397M.
FAQ
What kind of company is ALT?
ALT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALT?
The market cap of ALT is approximately $397M, ranking 3,345 within its sector.
What is the 52-week high and low for ALT?
ALT has recorded a 52-week high of $6.44 and a low of $2.02.
